MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 15, 2008; DOI: 10.1124/mol.108.050575


0026-895X/09/7503-677-684$20.00
Mol Pharmacol 75:677-684, 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.108.050575v1
75/3/677    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toriyabe, T.
Right arrow Articles by Yamazoe, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toriyabe, T.
Right arrow Articles by Yamazoe, Y.

Unveiling a New Essential Cis Element for the Transactivation of the CYP3A4 Gene by XenobioticsFormula

Takayoshi Toriyabe, Kiyoshi Nagata1, Tomonari Takada, Yusuke Aratsu, Tsutomu Matsubara, Kouichi Yoshinari, and Yasushi Yamazoe

Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan

Pregnane X receptor (PXR) has been shown to form a heterodimer with retinoid X receptor {alpha} (RXR{alpha}) and to bind to the distal nuclear receptor-binding element 1 and an everted repeat separated by six nucleotides in the proximal promoter of the CYP3A4 gene. In the present study, a new rifampicin-responsive region, located at -7.6 kilobases upstream from the transcription initiation site, has been identified using reporter assays in HepG2 cells. This region contains a cluster of possible nuclear receptor-binding half-sites, AG(G/T)TCA-like sequence. Of these putative half-sites, we focused six half-sites and termed them {alpha}-{eta} half-sites. Introduction of a mutation into either an {alpha} or β half-site of CYP3A4 reporter genes almost completely diminished the rifampicin-induced transcription. In electrophoretic mobility shift assays, PXR/RXR{alpha} heterodimer bound to the direct repeat separated by four nucleotides (DR4) formed with {alpha} and β half-sites. HepG2-based transactivation assays with the reporter gene constructs with or without mutations in the PXR binding element(s) demonstrated that this DR4 motif is essential for the transcriptional activation not only by rifampicin but also by various human PXR activators. In addition, reporter assays performed in human hepatocytes and mice with adenoviruses expressing luciferase derived from various CYP3A4 reporter genes and that expressing human PXR supported the results of experiments in HepG2 cells. These results suggest the obligatory role of the newly identified direct repeat separated by four nucleotides-type PXR binding element of the CYP3A4 gene for xenobiotic induction of CYP3A4.


Received for publication July 18, 2008.

Accepted for publication December 15, 2008.

Address correspondence to: Dr. Yasushi Yamazoe, Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-aoba, Aoba-ku, Sendai, Miyagi 980-8578, Japan. E-mail: yamazoe{at}mail.tains.tohoku.ac.jp




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
S. Tachibana, K. Yoshinari, T. Chikada, T. Toriyabe, K. Nagata, and Y. Yamazoe
Involvement of Vitamin D Receptor in the Intestinal Induction of Human ABCB1
Drug Metab. Dispos., August 1, 2009; 37(8): 1604 - 1610.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics